<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26312729</article-id>
      <article-id pub-id-type="pmc">4540563</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20153841</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Vemurafenib and cutaneous adverse events - report of five cases<xref ref-type="fn" rid="fn01">*</xref></article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Silva</surname>
            <given-names>Giselle de Barros</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mendes</surname>
            <given-names>Adriana Pessoa</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>de Macedo</surname>
            <given-names>Mariana Petaccia</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pinto</surname>
            <given-names>Cl&#xF3;vis Ant&#xF4;nio Lopes</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gibbons</surname>
            <given-names>Ivana Lameiras</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Duprat Neto</surname>
            <given-names>Jo&#xE3;o Pedreira</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <aff id="aff01"><label>1</label>AC Camargo Cancer Center - Liberdade (SP), Brazil</aff>
      </contrib-group>
      <author-notes>
        <corresp id="c01">MAILING ADDRESS: Giselle de Barros Silva, Rua Professor Antonio
Prudente, 211 Liberdade, 01509-010 - S&#xE3;o Paulo - SP, Brazil. E-mail:
<email>giselle_barros@yahoo.com.br</email></corresp>
        <fn fn-type="conflict">
          <p>Conflict of Interest: None.</p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>May-Jun</season>
        <year>2015</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>May-Jun</season>
        <year>2015</year>
      </pub-date>
      <volume>90</volume>
      <issue>3 Suppl 1</issue>
      <fpage>242</fpage>
      <lpage>246</lpage>
      <history>
        <date date-type="received">
          <day>15</day>
          <month>7</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>09</day>
          <month>9</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2015 by Anais Brasileiros de Dermatologia</copyright-statement>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Vemurafenib is a selective inhibitor of V600E-mutant BRAF protein used to treat
metastatic and unresectable melanoma. Clinical trials have shown increased overall
survival and progression-free survival in patients treated with Vemurafenib. However,
cutaneous adverse events are common during treatment. We report fi ve cases of
metastatic melanoma with BRAF V600E positivity, treated with Vemurafenib and its
cutaneous adverse events. Dermatologists and oncologists need to be aware of possible
skin changes caused by this medication, which is increasingly employed in melanoma
treatment. Monitoring of patients during therapy is important for early treatment of
adverse cutaneous cutaneous adverse events, improvement in quality of life and
adherence to treatment.</p>
      </abstract>
      <kwd-group>
        <kwd>Drug eruptions</kwd>
        <kwd>Drug therapy</kwd>
        <kwd>Melanoma</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>Vemurafenib selectively inhibits the BRAF V600E mutant protein. It is used in the
treatment of unresectable or metastatic melanoma with increased overall survival and
progression-free survival. <sup><xref rid="r01" ref-type="bibr">1</xref></sup></p>
      <p>BRAF mutation is the most common in human cancers (found in 40-60% of skin melanomas).
<sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r02" ref-type="bibr">2</xref></sup> Vemurafenib inhibits BRAF V600E, blocking the MAPK pathway and
preventing tumor cell proliferation. <sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r02" ref-type="bibr">2</xref></sup></p>
      <p>Cutaneous adverse events are common during treatment and include: photosensitivity,
keratosis pilaris-like rash, plantar hyperkeratosis, warts, cutaneous squamous cell
carcinoma (SCC) and keratoacanthoma.<sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r03" ref-type="bibr">3</xref></sup> There have been reports of darkening and
eruption of new nevi and second primary melanoma, panniculitis and skin sensitivity or
dermatitis by radiation recall on irradiated skin. <sup><xref rid="r04" ref-type="bibr">4</xref>-<xref rid="r09" ref-type="bibr">9</xref></sup></p>
      <p>In this article, we report five cases of BRAF V600E metastatic melanoma treated with
Vemurafenib, revealing cutaneous adverse events associated with treatment.</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <sec>
        <title>Case 1</title>
        <p>Female patient, aged 66, was diagnosed with nodular melanoma on her left leg in 2008.
In 2010, intransit metastases were resected. She was treated with IFN and ipilimumab,
with no response. Vemurafenib was administered in February 2013. She endured
photosensitivity, keratoacanthoma, actinic keratosis and alopecia (<xref ref-type="fig" rid="f01">Figure 1</xref>). After 6 months, treatment was
interrupted due to disease progression.</p>
        <fig id="f01" orientation="portrait" position="float">
          <label>FIGURE 1</label>
          <caption>
            <p>Case 1: Keratoacanthoma on the left mandibula <bold>(A)</bold> confi rmed by
histological analysis, hematoxylin-eosin, 20x <bold>(B)</bold>,
photosensitivity <bold>(C)</bold> and alopecia <bold>(D)</bold></p>
          </caption>
          <graphic xlink:href="abd-90-03-s1-0242-g01"/>
        </fig>
      </sec>
      <sec>
        <title>Case 2</title>
        <p>Male patient, aged 76, was diagnosed with superficial spreading melanoma on the left
arm in July 2009. In 2012, he developed metastases. In March 2013, he was started on
Vemurafenib. After 4 months, he developed well-differentiated SCC on the left forearm
(<xref ref-type="fig" rid="f02">Figure 2</xref>). In September 2013, Vemurafenib
was suspended due to acute respiratory symptoms.</p>
        <fig id="f02" orientation="portrait" position="float">
          <label>FIGURE 2</label>
          <caption>
            <p>Case 2: Hyperkeratotic and erithematous plaque on the left forearm developing
during Vemurafenib treatment <bold>(A)</bold>. Histological analysis revealing
well-differentiated squamous cell carcinoma, hematoxylin-eosin, 50x
<bold>(B)</bold></p>
          </caption>
          <graphic xlink:href="abd-90-03-s1-0242-g02"/>
        </fig>
      </sec>
      <sec>
        <title>Case 3</title>
        <p>Male patient, aged 71, was diagnosed with nodular melanoma on his right arm in 2009.
In October 2012, he developed metastases. In May 2013, he was started on Vemurafenib.
After a month, an irregular melanocytic lesion in the abdomen was identified, which
was a melanoma <italic>in situ</italic>. He endured a keratosis pilaris-like rash
thinning of hair, plantar hyperkeratosis, verrucous papillomas and SCC. After 5
months of treatment, there was a dermatoscopic alteration of the nevus on the right
thigh, with suspicion confocal microscopy, but the diagnosis was junctional nevus
(<xref ref-type="fig" rid="f03">Figure 3</xref>).</p>
        <fig id="f03" orientation="portrait" position="float">
          <label>FIGURE 3</label>
          <caption>
            <p>Case 3: Alopecia on the trunk before <bold>(A)</bold> and during Vemurafenib
treatment <bold>(B)</bold>. Hyperkeratosis of the feet <bold>(C)</bold>.
Dermoscopic changes in a melanocytic lesion on the right thigh, with increase
in dark-brown pigmentation and globules <bold>(D,E)</bold>. Histologic analysis
shows a junctional nevus. Hematoxylin- eosin, 100x <bold>(F)</bold></p>
          </caption>
          <graphic xlink:href="abd-90-03-s1-0242-g03"/>
        </fig>
      </sec>
      <sec>
        <title>Case 4</title>
        <p>Male patient, aged 49, was diagnosed in 2007 with superficial spreading melanoma on
the back. In 2010, he was diagnosed with metastases, underwent biochemotherapy
followed by ipilimumab, with no response. In February 2012, he was started on
Vemurafenib. Five months later, he showed dermatoscopic alteration of the nevus on
the back; the diagnosis was melanoma <italic>in situ</italic> (<xref ref-type="fig" rid="f04">Figure 4</xref>). In November 2012, Vemurafenib was discontinued due to
disease progression.</p>
        <fig id="f04" orientation="portrait" position="float">
          <label>FIGURE 4</label>
          <caption>
            <p>Case 4: Newly developed melanocytic lesion on the upper back <bold>(A)</bold>.
Dermoscopic analysis shows irregular, dark-brown pigmentation <bold>(B)</bold>,
with histological features of melanoma <italic>in situ</italic>. Hematoxylin-
eosin, 100x <bold>(C)</bold></p>
          </caption>
          <graphic xlink:href="abd-90-03-s1-0242-g04"/>
        </fig>
      </sec>
      <sec>
        <title>Case 5</title>
        <p>Female patient, aged 35, was diagnosed with superficial spreading melanoma in her
right leg in May 2012. She underwent wide excision, lymphadenectomy and treatment
with IL-2. In May 2013, she developed brain metastasis, started radiotherapy and
treatment with Vemurafenib. After 15 days, the irradiated area showed dermatitis,
which improved with topical steroids. Erythematous and painful nodules appeared on
the lower limbs, suggesting erythema nodosum (<xref ref-type="fig" rid="f05">Figure
5</xref>). CRP, ANA, RF, and alpha-1-antitrypsin were normal and the biopsy was
unsatisfactory. Oral corticosteroids were indicated for lesion control. She showed
decreased and increased pigmentation of some nevi and photosensitivity (<xref ref-type="fig" rid="f06">Figure 6</xref>). In December 2013, she died due to
disease progression.</p>
        <fig id="f05" orientation="portrait" position="float">
          <label>FIGURE 5</label>
          <caption>
            <p>Case 5: Radiation sensitivity on the scalp and face <bold>(A,B)</bold>.
Photosensitivity on the face <bold>(C,D)</bold> and right forearm
<bold>(E,F)</bold> before and after topical corticosteroid treatment.
Panniculitis on the left thigh <bold>(G)</bold></p>
          </caption>
          <graphic xlink:href="abd-90-03-s1-0242-g05"/>
        </fig>
        <fig id="f06" orientation="portrait" position="float">
          <label>FIGURE 6</label>
          <caption>
            <p>Case 5: Melanocytic lesion on the upper back thigh <bold>(A)</bold>.
Dermoscopic changes of the nevus, with increase in dark-brown pigmentation and
dots <bold>(C)</bold></p>
          </caption>
          <graphic xlink:href="abd-90-03-s1-0242-g06"/>
        </fig>
      </sec>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>Vemurafenib promotes the survival of patients with metastatic melanoma <sup><xref rid="r01" ref-type="bibr">1</xref></sup>. It inhibits the MAPK pathway by binding
to BRAF V600E, resulting in an antitumor effect in melanoma. <sup><xref rid="r02" ref-type="bibr">2</xref></sup> The most frequent adverse events are cutaneous 1-3.</p>
      <p>The proliferation of keratinocytes is common when using Vemurafenib, ranging from
benign, verrucous lesions to malignant, such as SCC. This appears early, usually between
the 7<sup>th</sup> and 8<sup>th</sup> weeks of treatment and seems to be caused by the
paradoxical activation of MAPK by Vemurafenib in cells with wild BRAF and RAS mutation
through CRAF dimers. <sup><xref rid="r02" ref-type="bibr">2</xref>,<xref rid="r03" ref-type="bibr">3</xref>,<xref rid="r10" ref-type="bibr">10</xref></sup> It is believed
that keratinocytes from sun-exposed areas in elderly patients with fair skin have RAS
mutations and their stimulation can cause skin tumors. <sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r02" ref-type="bibr">2</xref>,<xref rid="r10" ref-type="bibr">10</xref></sup></p>
      <p>Rashes are common and can be keratosis pilaris-like or maculopapular; they usually spare
the face. <sup><xref rid="r03" ref-type="bibr">3</xref>,<xref rid="r10" ref-type="bibr">10</xref></sup> They may coalesce, with the appearance of toxic erythema.
Normally, they are not severe enough to require discontinuation of treatment. <sup><xref rid="r03" ref-type="bibr">3</xref>,<xref rid="r10" ref-type="bibr">10</xref></sup></p>
      <p>Photosensitivity during treatment with Vemurafenib occurs after sun exposure. UVA
radiation plays an important role in pathogenesis and it permeates glass. Daily use of
sunscreen (minimum SPF 30 and broad UVA protection), appropriate clothing and
accessories and 100% UVA and UVB protective films on the windows of the car, house or at
work, are recommended. <sup><xref rid="r03" ref-type="bibr">3</xref>,<xref rid="r10" ref-type="bibr">10</xref></sup></p>
      <p>BRAF mutation is a common occurrence in melanocytic nevi. <sup><xref rid="r04" ref-type="bibr">4</xref></sup> It is presumed that Vemurafenib action in these cases
induces involution, whereas wild BRAF nevi would undergo paradoxical activation of MAPK
pathway and atypia. <sup><xref rid="r04" ref-type="bibr">4</xref>,<xref rid="r05" ref-type="bibr">5</xref></sup> A second primary melanoma caused by Vemurafenib has been
reported. <sup><xref rid="r05" ref-type="bibr">5</xref></sup> BRAF V600E metastases
respond to Vemurafenib, whereas wild BRAF melanomas would be activated. <sup><xref rid="r05" ref-type="bibr">5</xref></sup> Digital dermoscopy performed before
therapy with a monthly follow-up enables identification of suspicious lesions, while
confocal microscopy can be complementary. <sup><xref rid="r05" ref-type="bibr">5</xref></sup> Skin biopsy is useful for diagnostic confirmation.</p>
      <p>Panniculitis associated with Vemurafenib treatment has been described. <sup><xref rid="r06" ref-type="bibr">6</xref>,<xref rid="r07" ref-type="bibr">7</xref></sup>
It may appear along with fever, arthritis and arthralgia. In general, biopsies reveal
the presence of predominantly lobular neutrophilic panniculitis. <sup><xref rid="r07" ref-type="bibr">7</xref></sup> It can be treated with oral
corticosteroids, anti-inflammatory and discontinuation of Vemurafenib, when it is too
symptomatic. Expectant follow-up is an option in milder cases. <sup><xref rid="r06" ref-type="bibr">6</xref></sup></p>
      <p>Vemurafenib can cause sensitivity in the irradiated skin and can be added to the list of
drugs that trigger radiation recall dermatitis. Topical corticosteroids relieve
symptoms. <sup><xref rid="r08" ref-type="bibr">8</xref></sup> Camidge et al. suggested
that skin reactions caused by drugs administered up to 7 days after radiotherapy should
be considered radiosensitization reactions, rather than radiation recall. <sup><xref rid="r09" ref-type="bibr">9</xref></sup></p>
      <p>Dermatologists and oncologists must be aware of skin reactions caused by Vemurafenib and
schedule routine appointments during therapy. We recommend dermatologic evaluation with
dermoscopy before the start of treatment, after 4 weeks and every 8 weeks, together with
confocal microscopy, for better assessment of these lesions, whenever possible.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="supported-by">
        <p>Financial Support: None</p>
      </fn>
      <fn fn-type="other">
        <p><bold>How to cite this article:</bold> Silva GB, Mendes AP, Macedo MP, Pinto CAL,
Gibbons IL, Duprat Neto JP. Vemurafenib and adverse cutaneous events - report of fi
ve cases. An Bras Dermatol. 2015;90(3 Supl 1):S242-6.</p>
      </fn>
      <fn fn-type="other" id="fn01">
        <label>*</label>
        <p>Work performed at the N&#xFA;cleo de C&#xE2;ncer de Pele do AC Camargo Cancer Center -
Liberdade (SP), Brazil.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chapman</surname>
              <given-names>PB</given-names>
            </name>
            <name>
              <surname>Hauschild</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Robert</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Haanen</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Ascierto</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Larkin</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Improved Survival with Vemurafenib in Melanoma with BRAF V600E
mutation</article-title>
          <source>N Engl J Med</source>
          <year>2011</year>
          <volume>364</volume>
          <fpage>2507</fpage>
          <lpage>2516</lpage>
          <pub-id pub-id-type="pmid">21639808</pub-id>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Huang</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Hepper</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Anadkat</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cornelius</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Cutaneous toxic effects associated with vemurafenib and inhibition of
the BRAF pathway</article-title>
          <source>Arch Dermatol</source>
          <year>2012</year>
          <volume>148</volume>
          <fpage>628</fpage>
          <lpage>633</lpage>
          <pub-id pub-id-type="pmid">22431713</pub-id>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lacouture</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Duvic</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hauschild</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Prieto</surname>
              <given-names>VG</given-names>
            </name>
            <name>
              <surname>Robert</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Schadendorf</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Analysis of dermatologic events in vemurafenib-treated patients with
melanoma</article-title>
          <source>Oncologist</source>
          <year>2013</year>
          <volume>18</volume>
          <fpage>314</fpage>
          <lpage>322</lpage>
          <pub-id pub-id-type="pmid">23457002</pub-id>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haenssle</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Kraus</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Brehmer</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Kretschmer</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>V&#xF6;lker</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Asper</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Dynamic changes in nevi of a patient with melanoma treated with
vemurafenib: importance of sequential dermoscopy</article-title>
          <source>Arch Dermatol</source>
          <year>2012</year>
          <volume>148</volume>
          <fpage>1183</fpage>
          <lpage>1185</lpage>
          <pub-id pub-id-type="pmid">22911096</pub-id>
        </element-citation>
      </ref>
      <ref id="r05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dalle</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Poulalhon</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Debarbieux</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Zaharia</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Mihm</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Lacouture</surname>
              <given-names>ME</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Tracking of second primary melanomas in vemurafenib-treated
patients</article-title>
          <source>JAMA Dermatol</source>
          <year>2013</year>
          <volume>149</volume>
          <fpage>488</fpage>
          <lpage>490</lpage>
          <pub-id pub-id-type="pmid">23715012</pub-id>
        </element-citation>
      </ref>
      <ref id="r06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maldonado-Seral</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Berros-Fombella</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Vivanco-Allende</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Coto-Segura</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Vazquez-Lopez</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Perez-Oliva</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Vemurafenib-associated neutrophilic panniculitis: An emergent adverse
effect of variable severity</article-title>
          <source>Dermatol Online J</source>
          <year>2013</year>
          <volume>19</volume>
          <fpage>16</fpage>
          <lpage>16</lpage>
          <pub-id pub-id-type="pmid">24021375</pub-id>
        </element-citation>
      </ref>
      <ref id="r07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zimmer</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Livingstone</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Hillen</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>D&#xF6;mkes</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Becker</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Schadendorf</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Panniculitis with arthralgia in patients with melanoma treated with
selective BRAF inhibitors and its management</article-title>
          <source>Arch Dermatol</source>
          <year>2012</year>
          <volume>148</volume>
          <fpage>357</fpage>
          <lpage>361</lpage>
          <pub-id pub-id-type="pmid">22250191</pub-id>
        </element-citation>
      </ref>
      <ref id="r08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Boussemart</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Boivin</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Claveau</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Tao</surname>
              <given-names>YG</given-names>
            </name>
            <name>
              <surname>Tomasic</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Routier</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Vemurafenib and radiosensitization</article-title>
          <source>JAMA Dermatol</source>
          <year>2013</year>
          <volume>149</volume>
          <fpage>855</fpage>
          <lpage>857</lpage>
          <pub-id pub-id-type="pmid">23699661</pub-id>
        </element-citation>
      </ref>
      <ref id="r09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Camidge</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Price</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Characterizing the phenomenon of radiation recall
dermatitis</article-title>
          <source>Radiother Oncol</source>
          <year>2001</year>
          <volume>59</volume>
          <fpage>237</fpage>
          <lpage>245</lpage>
          <pub-id pub-id-type="pmid">11369064</pub-id>
        </element-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sinha</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Edmonds</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Newton-Bishop</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Gore</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Larkin</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Fearfield</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Adverse cutaneous events associated with vemurafenib in patients with
metastatic melanoma: practical advice on diagnosis, prevention and management of
the main treatment-related skin toxicities</article-title>
          <source>Br J Dermatol</source>
          <year>2012</year>
          <volume>167</volume>
          <fpage>987</fpage>
          <lpage>994</lpage>
          <pub-id pub-id-type="pmid">22913467</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
